Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

/a>

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL, that the substitution of pixantrone for doxorubicin in the CHOP regimen may not produces complete remissions and long-term disease free survival in patients with relapsed or refractory, aggressive NHL who previously failed frontline CHOP therapy, that there may not be a correlation between CR/CRu's and progression free survival, that pixantrone may not show an overall improvement rate in survival for patients independent of factors known to influence survival, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI cannot predict whether PIX-R will serve as either a post-marketing commitment trial or as a pivotal trial, that CTI cannot predict the outcome of the formal dispute resolution process with the FDA, that the FDA may not make its decision on the appeal in the second quarter of 2011, that the FDA may request additional clinical trials, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Sept. 15, 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Richard King, President and Chief Executive Officer, will present ... over the coming weeks as follows: UBS ...
... NEW YORK, Sept. 15, 2011 Reportlinker.com ... is available in its catalogue: ... 2010-2014 http://www.reportlinker.com/p0240543/Global-Blood-Glucose-Test-Strips-Market-2010-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Blood Glucose Test Strips market to grow ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September 2Global Blood Glucose Test Strips Market 2010-2014 2
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... The Association for Molecular Pathology (AMP) released a ... Diagnostics on recommendations for a molecular diagnostics ... of education. The report was prepared by the ... the AMP Training and Education Committee. "Our goal ... future medical laboratory scientists appropriately in order to ...
(Date:4/22/2014)... rabbits, Johns Hopkins scientists have found a way to ... the development of atherosclerosis, the main cause of heart ... among humans. The condition develops when fat builds inside ... and hardened, greatly reducing their ability to feed oxygen-rich ... In a series of experiments, described April 7 in ...
(Date:4/22/2014)... German . , ... their mode of action is complex: In low concentrations ... while at high concentrations they can cause "oxidative stress", ... redox signaling unfolds in single cells and organelles in ... jointly by the teams of LMU Professor Martin Kerschensteiner ...
(Date:4/22/2014)... in massive health care spending, a new RAND study ... to incentivize pharmaceutical companies and device makers to develop ... existing medical technologies and their use, a new study ... and medical devices get created in the first place. ... with as little loss of health as possible and ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... New Quads Have ... Bottles , ... April 15, 2010 -- Tahitian Noni International (TNI) announced its new bioactive ... the network marketing industry. The new Tahitian Noni 4-liter Quad is designed to be placed ...
... ... of court a Workers’ Compensation claim for the amount of $34,000.00. , ... New Bedford, MA (PRWEB) April, 15, 2010 -- The law firm ... $34,000.00., , , , ,The employee was injured while on the job while working as a ...
... ... to facilitate a speedy recovery from one of the world’s worst natural disasters. The monies ... the rebuilding of Haiti. MBMI hopes that this initiative will inspire others to do the ... Delray Beach, Florida ...
... poor management of related condition leaves many undiagnosed, , ... Britain often fail to detect cases of chlamydia in ... British researchers contend. , They say that many urologists ... condition known as epididymo-orchitis, which causes inflammation of the ...
... well for golden years, study finds , THURSDAY, April 15 ... of old age is taking pleasure in your grandchildren, but ... social life, being married and having a partner who is ... of life, but having children or grandchildren matters little, the ...
... procedures will help save lives long-term , THURSDAY, April 15 ... nearing a "state of crisis" and needs to be repaired ... a new government report. , The authors of the ... conducted by the Institute of Medicine (IOM), calls for a ...
Cached Medicine News:Health News:Quad - The First 4-Liter Refrigerator Dispenser Introduced by Tahitian Noni International 2Health News:MBMI Steel Buildings is Saving Haiti One Building at a Time 2Health News:Friends, Not Grandkids, Key to Happy Retirement 2Health News:Friends, Not Grandkids, Key to Happy Retirement 3Health News:Experts Urge Fixes for Clinical Trials System in 'Crisis' 2Health News:Experts Urge Fixes for Clinical Trials System in 'Crisis' 3Health News:Experts Urge Fixes for Clinical Trials System in 'Crisis' 4
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
... , Standby: All toggle switches at off (center position) ... Hz separated by .75 s; repeats every 10 s ... , Tetanus: 50 Hz (50 pulses/s) or 100 ... repeat (4 pulses/2 s; repeats every 10 s) , ...
... switch maintains power to the instrument without generating stimulus ... 50 Hz separated by .75 s; repeats every 10 ... (2 pulses/s) , Tetanus: 50 Hz (50 pulses/s) ... s; repeats every 10 s , Output Current: Adjustable ...
Medicine Products: